Business context and reporting period
Emerald Medical Applications Corp. (formerly Zaxis International Inc.) filed this unaudited Form 10-Q for the quarter ended September 30, 2015. On July 14, 2015, it completed a reverse merger with Emerald Medical Applications Ltd., an Israeli digital-health startup developing and marketing DermaCompare skin-imaging and analytics software. The filing’s registrant is Emerald Medical Applications Corp.; this differs from the company name in the request metadata and should be verified.
Financial performance and position
- Revenue: $0 for both the three and nine months ended September 30, 2015, and for the comparable 2014 periods. Gross margin is not meaningful because there was no revenue.
- Net loss: $7.235 million for the quarter and $7.675 million for the nine-month period, versus no reported loss in 2014. The quarterly statements report $7,234,711; MD&A instead states $7,243,711.
- Expenses: Nine-month operating expenses were $1.658 million, including $499,898 of research and development and $539,121 of general and administrative expense. Other expense included $5.343 million of stock-based compensation and a $678,027 loss on debt settlement. These items substantially increased reported losses and were largely non-cash.
- Cash flow: Nine-month operating cash use was $831,984; investing activities provided $441,378, including $467,380 attributed to the reverse merger; financing activities provided $852,071. Cash increased from $14,411 at year-end 2014 to $447,029.
- Liquidity and debt: Current assets were $458,841 and current liabilities $314,140, including $82,071 of short-term notes and $29,719 of convertible notes. The resulting working capital is $144,701 using the balance-sheet figures; MD&A reports $167,961. Total liabilities were $314,140.
- Equity and shares: The balance sheet reports 14,807,805 common shares outstanding at September 30, 2015; the filing reports 15,063,555 outstanding on November 20. The filing’s equity subtotal is inconsistent: its components sum to $167,961, while the stated total is $167,941.
Material changes versus the prior comparable period
The company had no revenue or reported operating expenses in the 2014 comparison periods; 2015 results include Emerald’s operations following the July reverse merger, increased research and development and administrative costs, and substantial warrant-based compensation. Cash rose from $14,411 at December 31, 2014, supported by equity and debt financing and the merger. Current liabilities increased from $137,635 to $314,140.
Outlook, risks, contingencies, and unusual items
- Management anticipated significantly increased activity in the fourth quarter of 2015 and expected significant DermaCompare revenue to begin in or before the first half of 2016. These are forward-looking expectations, not reported results.
- Management estimated that up to an additional $1.5 million might be required over the next 12 months to implement its plan and fund operations. The filing states that cash was insufficient for the business plan, there was no established revenue source, and substantial doubt existed about the company’s ability to continue as a going concern.
- On November 9, 2015, former Israeli counsel asserted a claim for unpaid legal fees. The company accrued $118,430, representing 80% of the claim, and said it believed it had meritorious defenses.
- Management concluded disclosure controls and procedures were not effective as of quarter-end. The filing states that no remediation had been made during the quarter.
- Consultants received fully vested Class B and C warrants valued at $5.343 million in total. Separately, the company recorded a $678,027 debt-settlement loss when Emerald debt holders converted debt into shares and warrants.
Important facts for investors to verify
- Confirm the issuer’s identity and whether the filing corresponds to the company named in the request metadata.
- Reconcile the stated working capital and stockholders’ equity totals with the balance-sheet figures and components.
- Resolve the $9,000 difference between the quarterly net loss in the financial statements and MD&A.
- Assess the timing and likelihood of projected revenue, the need for additional financing, and the company’s going-concern risk.
- Review the former-counsel claim, the accounting and valuation of warrant compensation and debt settlement, and potential share dilution.